HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome.
about
Nonhuman primate models for HIV/AIDS vaccine developmentRevealing the role of CD4(+) T cells in viral immunityA global approach to HIV-1 vaccine developmentA human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques.Induction of Gag-specific CD4 T cell responses during acute HIV infection is associated with improved viral control.Vaccination with Gag, Vif, and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239Proteome-wide analysis of HIV-specific naive and memory CD4(+) T cells in unexposed blood donors.Immunity to HIV in Early LifeComprehensive analysis of contributions from protein conformational stability and major histocompatibility complex class II-peptide binding affinity to CD4+ epitope immunogenicity in HIV-1 envelope glycoprotein.Characterization of HIV-specific CD4+ T cell responses against peptides selected with broad population and pathogen coverage.Strategy for identifying dendritic cell-processed CD4+ T cell epitopes from the HIV gag p24 protein.HIV-1 conserved elements p24CE DNA vaccine induces humoral immune responses with broad epitope recognition in macaquesBroad and cross-clade CD4+ T-cell responses elicited by a DNA vaccine encoding highly conserved and promiscuous HIV-1 M-group consensus peptides.Immunogenetics of small ruminant lentiviral infectionsAntibody persistence and T-cell balance: two key factors confronting HIV vaccine development.HIV control is mediated in part by CD8+ T-cell targeting of specific epitopes.IL-10-producing B cells are induced early in HIV-1 infection and suppress HIV-1-specific T cell responses.Hantaan virus infection induces both Th1 and ThGranzyme B+ cell immune responses that associated with viral control and clinical outcome in humansAfrican green monkey TRIM5α restriction in simian immunodeficiency virus-specific rhesus macaque effector CD4 T cells enhances their survival and antiviral function.HLA Class-II Associated HIV Polymorphisms Predict Escape from CD4+ T Cell Responses.HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost.HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in MiceAviremia 10 Years Postdiscontinuation of Antiretroviral Therapy Initiated During Primary Human Immunodeficiency Virus-1 Infection and Association With Gag-Specific T-Cell ResponsesCD8+ and CD4+ cytotoxic T cell escape mutations precede breakthrough SIVmac239 viremia in an elite controllerAlternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectorsHIV-1 Antibody Neutralization Breadth Is Associated with Enhanced HIV-Specific CD4+ T Cell ResponsesRobust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge.Public T cell receptors confer high-avidity CD4 responses to HIV controllersMucosal immunology of HIV infection.Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection.Cyclophilin A as a potential genetic adjuvant to improve HIV-1 Gag DNA vaccine immunogenicity by eliciting broad and long-term Gag-specific cellular immunity in mice.Antiviral CD8+ T Cells Restricted by Human Leukocyte Antigen Class II Exist during Natural HIV Infection and Exhibit Clonal Expansion.Factors Associated with the Size of HIV DNA Reservoir.Association of HLA-DRB1-restricted CD4⁺ T cell responses with HIV immune controlRecent advances in research of HIV infection: implications of viral and host genetics on treatment and prevention.Preserving HIV-specific T cell responses: does timing of antiretroviral therapy help?Justification for the inclusion of Gag in HIV vaccine candidates.Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.HIV Controllers Exhibit Enhanced Frequencies of Major Histocompatibility Complex Class II Tetramer+ Gag-Specific CD4+ T Cells in Chronic Clade C HIV-1 Infection.
P2860
Q26861148-8C0ABBF4-8EEA-45CE-97F7-967E31880FF8Q26995409-3E92ED3A-0627-4514-A496-E5F03ACA41E5Q27024614-28C17F3B-C08E-4840-9CDF-0E22D99F9339Q30934059-D233C5CA-7AFA-42A1-8CB6-D4761748270CQ33744069-037FEE4B-04A4-46FB-B1DB-608E3C5EAFAFQ33744109-61B01D24-9D26-4DAD-BF15-A616FD2BDFE5Q33826872-906E0F23-C44D-40B1-95AC-6CFD35D97EDCQ34033051-A89165A6-D0B7-4387-AB32-BAFF3D22136AQ34059460-934A95BC-2B08-411B-A430-7D4FEB40AB8BQ34335751-17D3B684-CB2F-433E-A310-C2CB40F07C51Q34364276-0F0C2040-0980-494D-B07B-4840683AFAFFQ34388606-5812437E-5106-438B-B8E3-DD2F820C9856Q34428561-E9263DFE-B9DC-4435-BF73-FFF1D152D421Q34434913-ED570915-17EE-4573-B4F7-618964136277Q34480617-BB7F684C-BEFF-4572-859E-E2DC5A6F0162Q34594538-EA398139-0997-4048-B7DD-82D6A60ACA35Q35106912-72D80196-D68B-4417-A5B4-E998C6370D33Q35251129-5F7BCFEE-FB5D-4667-8C00-90734CE4C763Q35641022-C35BBCDA-C3E1-401E-9C77-596759A9CB65Q35753766-75494AAD-BD8E-4962-A6DE-9B53CEA85E4BQ35883997-1BFF6085-79BB-40BD-A4B1-12B3DEBFE77BQ36079913-8B6A7C39-B107-4F43-9961-1BDCC29DC2B7Q36319368-275575BC-E6FA-414D-864D-D7A95C452F95Q36394661-8B1E4EC0-255C-4413-9291-B823B246D00DQ36559904-B1740AC5-4399-4C8B-A6F1-12718480D2F0Q36736860-60F453F2-1657-4685-B739-97402C0AA0FEQ36759963-F0579203-A974-4C14-A8F1-02D9DE7E14A5Q36798324-F1B76244-9E18-4DEC-8625-3E9550EE6779Q36951735-4BB13EA1-BD84-4A7B-BE3D-A491BE5D5256Q36957775-8B45F616-194A-4986-99FE-4B7D8F5DB93CQ37187509-A95389DA-090E-4706-8596-FDC06C44CA6EQ37309264-4BF7E2E0-95AA-4DDB-9F44-5039E3102E5BQ37362291-39CF26F5-A0CA-48EC-94D7-F84C20A18CA2Q37615584-B1E5DE69-771C-4418-A904-CE4F739507DCQ37682303-1F8FF16F-CDAD-469B-9040-C8CF66884FFEQ38095239-45D2F4D0-0676-4A1F-B4F9-2E5197919EE6Q38267445-052DFD03-F034-4692-B516-619DC9E99340Q38662319-A73E6AFC-3B8D-404E-A8D1-3D7172358E51Q38897238-E8EE5265-CD72-4608-B0B5-DEA76CE6AB00Q39026150-F8B22DE1-0947-4AC8-B166-1B71A7D38A8F
P2860
HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
HIV-specific CD4 T cell respon ...... ral load and clinical outcome.
@ast
HIV-specific CD4 T cell respon ...... ral load and clinical outcome.
@en
type
label
HIV-specific CD4 T cell respon ...... ral load and clinical outcome.
@ast
HIV-specific CD4 T cell respon ...... ral load and clinical outcome.
@en
prefLabel
HIV-specific CD4 T cell respon ...... ral load and clinical outcome.
@ast
HIV-specific CD4 T cell respon ...... ral load and clinical outcome.
@en
P2093
P2860
P50
P356
P1433
P1476
HIV-specific CD4 T cell respon ...... ral load and clinical outcome.
@en
P2093
Damien Z Soghoian
Isaiah Davis
Madelene Lindqvist
Michael Flanders
Musie Ghebremichael
Sam Cutler
Srinika Ranasinghe
P2860
P304
P356
10.1128/JVI.05577-11
P407
P577
2011-10-26T00:00:00Z